查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954609

全球人类抗凝血酶市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Human Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 100 Pages | 商品交期: 请询问到货日

价格

人类抗凝血酶市场成长驱动因子

2025年全球人抗凝血酶市场规模为3.8132亿美元，预计将从2026年的3.9634亿美元成长至2034年的5.6636亿美元，在预测期（2026-2034年）内年复合成长率（CAGR）为4.56%。2025年，欧洲凭藉强大的血浆分离基础设施和主要生产商的存在，以43.17%的市场占有率占据主导地位。

人类抗凝血酶是一种血浆来源的糖蛋白，它透过灭活凝血酶和其他丝氨酸蛋白酶，在调节血液凝固中发挥着非常重要的作用。它广泛用于预防异常血液凝固，尤其适用于遗传性抗凝血酶缺乏症患者以及高风险手术和重症监护环境。

市场概览

人类抗凝血酶浓缩物对于凝血障碍的治疗非常重要，尤其对接受复杂手术的患者以及血栓形成和瀰漫性血管内凝血（DIC）患者而言意义重大。心血管疾病盛行率的上升、器官移植手术数量的增加以及体外膜氧合（ECMO）的广泛应用是市场成长的主要驱动因素。

该市场的主要参与者包括CSL、Octapharma AG、Grifols、S.A.、Kedrion S.p.A.、Takeda Pharmaceutical Company Limited。这些公司在血浆衍生药物领域拥有强大的影响力，推动了整体市场成长。

市场动态

市场驱动因素

治疗应用的日益广泛

主要的成长驱动因素是人类抗凝血酶治疗应用的不断扩展。需要心臟手术、器官移植和抗凝血治疗的危重患者数量不断增加，推动了市场需求。根据2024年6月发表于Annals of Thoracic Surgery Short Reports的一篇文章 ，美国每年平均每10万人接受271.5例心臟手术。

遗传性抗凝血酶缺乏症影响全球约0.02%至0.05%的人口，因此需要终身替代疗法。外科医生和重症监护室（ICU）医生越来越依赖速效抗凝血酶製剂，预计该市场将从2026年的3.9634亿美元成长到2034年的5.6636亿美元。

市场限制因子

安全性问题和副作用

儘管血浆来源的抗凝血酶浓缩物已广泛用于治疗，但仍存在一定的风险。这些不良反应包括过敏反应、过敏性休克、出血併发症和血栓栓塞。儘管采取了严格的安全措施，但仍存在传播未知病原体的风险，儘管这种风险很小。在严重败血症病例中，高剂量抗凝血酶 III 和肝素合併使用可能会增加出血风险。这些因素限制了其在某些临床场景中的应用。

市场机会

联合疗法的发展

联合疗法研究的进展创造新的机会。研究表明，抗凝血酶和肝素的联合使用具有协同抗凝血作用。医疗专业人员积极探索此类联合疗法增强疗效的潜力。将适应症扩展到遗传性缺陷以外的领域，尤其是在败血症和瀰漫性血管内凝血（DIC）的治疗方面，预计将带来长期的成长机会。

市场挑战

复杂的监理与偿付框架

血浆衍生产品的严格监管要求延缓了产品审批和商业化的进程。此外，各国偿付政策的差异限制了产品的可及性，尤其是在中低收入国家。儘管临床需求旺盛，但这些挑战可能会抑制市场渗透。

市场趋势

临床应用范围的扩大

抗凝血酶的应用范围日益广泛，已不再局限于治疗遗传性凝血功能障碍。在日本，抗凝血酶浓缩物已被纳入败血症合併瀰漫性血管内凝血（DIC）患者的抗凝血治疗标准方案。日本医疗体系核准的每日剂量为1500国际单位。这种临床应用范围的扩大代表着一个重要的市场趋势。

市场区隔分析

依应用领域划分

市场依应用领域分为治疗应用与研究/诊断应用。

  • 2024年，治疗应用占据市场主导地位，并因临床需求旺盛而持续保持领先地位。抗凝血酶替代疗法广泛用于治疗肝素抵抗，2024年12月，美国血液学会推荐抗凝血酶替代疗法作为此类病例的首选治疗方案。
  • 另一方面，由于产品供应有限，研究/诊断应用领域的市场占有率较小。

依剂型划分

市面上依剂型分为冻干粉剂和液体剂。

  • 2024年，冻干粉剂因其稳定性较佳且易于储存，占据了主要市场占有率。 THROMBATE III（Griffols）和Thrombotrol VF（CSL）等产品均以冷冻干燥粉末形式供应。
  • 由于市售产品数量有限，液体剂型市场占有率较小。

依最终使用者划分

市场包括医院和诊所、製药和生物技术公司以及研究机构。

  • 2024年，由于外科手术和重症监护环境中使用量的增加，医院和诊所占据了最大的市场占有率。
  • 由于研究应用范围的扩大，製药和生物技术公司预计将稳定成长。

区域展望

欧洲

到2025年，欧洲以1.6462亿美元的市场规模和43.17%的市场占有率引领市场。其成长得益于强大的血浆生产基础设施、政府支持措施（例如 "法国2030" 计画）以及LFB和Griffols等领先企业的存在。

亚太地区

由于先天性缺陷病例数量的增加以及战略合作伙伴关係的建立，预计亚太地区将实现最快的成长。例如，2019年，SK Pharma 与 BioPharma Indonesia 合作开展了一项血浆生产计画。

北美

由于监管障碍限制了产品审批，北美市场占有率相对较小。

世界其他地区

预计拉丁美洲以及中东和非洲地区将实现温和成长，这主要得益于医疗保健可近性的提高。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 关键因素注意事项

  • 主要心血管疾病盛行率：依主要国家划分
  • 监理状况：依主要国家划分
  • 关键产业趋势（併购、业务合作、核准、上市等）

第5章 全球人类抗凝血酶市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依应用领域划分
    • 治疗应用
    • 研究与诊断
  • 市场分析、洞察与预测：依剂型划分
    • 冷冻干燥粉剂
    • 液体製剂
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 製药公司与生技产业
    • 研究机构
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区（ROW）

第6章 北美人类抗凝血酶市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲人类抗凝血酶市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家国家/地区

第8章 亚太地区人类抗凝血酶市场分析：洞察与预测（2021-2034）

  • 国家细分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 东南亚
    • 其他亚太地区

第9章 其他地区（ROW）人类抗凝血酶市场分析：洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • CSL
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
    • Grifols, S.A.
    • Medix Biochemica
    • Kedrion S.p.A.
    • Scripps Laboratories
Product Code: FBI113611

Growth Factors of human antithrombin Market

The global human antithrombin market was valued at USD 381.32 million in 2025 and is projected to grow from USD 396.34 million in 2026 to USD 566.36 million by 2034, registering a CAGR of 4.56% during the forecast period (2026-2034). In 2025, Europe dominated the market with a 43.17% share, supported by strong plasma fractionation infrastructure and the presence of leading manufacturers.

Human antithrombin is a plasma-derived glycoprotein that plays a vital role in regulating blood coagulation by inactivating thrombin and other serine proteases. It is widely used for preventing abnormal blood clotting, particularly in patients with hereditary antithrombin deficiency and in high-risk surgical or critical care settings.

Market Overview

Human antithrombin concentrates are essential in managing coagulation disorders, especially in patients undergoing complex surgical procedures or those suffering from thrombophilia and disseminated intravascular coagulation (DIC). The growing prevalence of cardiovascular diseases, increasing organ transplant procedures, and rising use of extracorporeal membrane oxygenation (ECMO) are key factors contributing to market expansion.

Major companies operating in this market include CSL, Octapharma AG, Grifols, S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited. Their strong presence in plasma-derived medicinal products strengthens overall market growth.

Market Dynamics

Market Drivers

Increasing Usage for Therapeutic Applications

The primary growth driver is the expanding therapeutic application of human antithrombin. The rising number of cardiac surgeries, organ transplants, and critically ill patients requiring anticoagulant therapy is increasing demand. According to a June 2024 article published in Annals of Thoracic Surgery Short Reports, the annual average cardiac surgery volume in the U.S. reached 271.5 procedures per 100,000 population.

Hereditary antithrombin deficiency affects approximately 0.02% to 0.05% of the global population, creating sustained demand for lifelong supplementation therapy. Surgeons and ICU physicians increasingly depend on fast-acting antithrombin formulations, supporting market growth from USD 396.34 million in 2026 to USD 566.36 million by 2034.

Market Restraints

Safety Concerns and Side Effects

Despite widespread therapeutic use, plasma-derived antithrombin concentrates carry certain risks. These include allergic reactions, anaphylaxis, bleeding complications, and thromboembolic events. There is also a minimal risk of transmission of unknown infectious agents, despite rigorous safety measures. In cases of severe sepsis, high-dose antithrombin III combined with heparin may increase hemorrhage risk. These factors limit adoption in certain clinical scenarios.

Market Opportunities

Expansion into Combination Therapies

Growing research on combination therapies is creating new opportunities. Studies indicate that combining antithrombin with heparin produces synergistic anticoagulant effects. Healthcare professionals are increasingly exploring such combinations to enhance therapeutic outcomes. The expansion of applications beyond hereditary deficiency, particularly in sepsis and DIC management, is expected to provide long-term growth opportunities.

Market Challenges

Complex Regulatory and Reimbursement Frameworks

Strict regulatory requirements for plasma-derived products slow product approvals and commercialization timelines. Additionally, reimbursement disparities across countries limit accessibility, especially in low- and middle-income nations. These challenges can restrain market penetration despite clinical demand.

Market Trends

Expanding Clinical Applications

Antithrombin is increasingly used beyond hereditary deficiency treatment. In Japan, anticoagulation therapy for septic patients with DIC includes antithrombin concentrate as part of standard care. A dose of 1,500 IU/day has been approved within the Japanese healthcare system. Such expanded clinical applications represent a notable market trend.

Segmentation Analysis

By Application

The market is segmented into therapeutic and research & diagnostic applications.

  • The therapeutic segment dominated the market in 2024 and continues to lead due to high clinical demand. Antithrombin supplementation is widely used to manage heparin resistance. In December 2024, the American Society of Hematology highlighted antithrombin supplementation as a preferred treatment in such cases.
  • The research & diagnostic segment holds a smaller share due to limited product availability.

By Dosage Form

The market is categorized into lyophilized powder and liquid formulations.

  • Lyophilized powder held the dominant share in 2024, owing to enhanced stability and ease of storage. Products such as THROMBATE III (Grifols) and Thrombotrol VF (CSL) are available in this form.
  • The liquid segment accounts for a smaller share due to limited commercial availability.

By End User

The market includes hospitals & clinics, pharmaceutical & biotechnology companies, and research institutes.

  • Hospitals & clinics held the largest share in 2024 due to increased usage in surgical and critical care settings.
  • The pharmaceutical and biotechnology segment is expected to grow steadily due to expanding research applications.

Regional Outlook

Europe

Europe led the market with a value of USD 164.62 million in 2025 and a 43.17% market share. Growth is driven by strong plasma manufacturing infrastructure, supportive government initiatives such as "France 2030," and the presence of major players like LFB and Grifols.

Asia Pacific

Asia Pacific is projected to witness the fastest growth due to rising congenital deficiency cases and strategic collaborations. For example, in 2019, SK Pharma partnered with BioPharma Indonesia for plasma production initiatives.

North America

North America holds a comparatively smaller share due to regulatory hurdles limiting product approvals.

Rest of the World

Latin America and the Middle East & Africa are experiencing gradual growth, supported by improving healthcare access.

Competitive Landscape

The market is semi-consolidated, with leading players including CSL, Grifols, Kedrion, and Octapharma AG. These companies maintain strong global distribution networks and plasma-derived product portfolios. Strategic collaborations, facility expansions, and clinical trials are shaping the competitive environment.

Conclusion

The global human antithrombin market is expected to grow steadily from USD 381.32 million in 2025 to USD 566.36 million by 2034, driven by rising surgical procedures, increasing cases of hereditary deficiency, and expanding therapeutic applications. While safety concerns and regulatory complexities present challenges, ongoing research, combination therapies, and strong European leadership are likely to sustain long-term market expansion. As healthcare systems continue to prioritize advanced anticoagulation management, human antithrombin will remain a critical component in treating complex coagulation disorders worldwide.

Segmentation By Application

  • Therapeutic
  • Research & Diagnostic

By Dosage Form

  • Lyophilized Powder
  • Liquid

By End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region

  • North America (By Application, Dosage Form, End User, and Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
  • 4.2. Regolatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research & Diagnostic
  • 5.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.2.1. Lyophilized Powder
    • 5.2.2. Liquid
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research & Diagnostic
  • 6.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.2.1. Lyophilized Powder
    • 6.2.2. Liquid
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research & Diagnostic
  • 7.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.2.1. Lyophilized Powder
    • 7.2.2. Liquid
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. UK
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research & Diagnostic
  • 8.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.2.1. Lyophilized Powder
    • 8.2.2. Liquid
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. South Korea
    • 8.4.6. Southeast Asia
    • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research & Diagnostic
  • 9.2. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.2.1. Lyophilized Powder
    • 9.2.2. Liquid
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. CSL
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. Financials (Based on Availability)
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. SWOT,Etc.
    • 10.2.2. Octapharma AG
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. Financials (Based on Availability)
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. SWOT,Etc.
    • 10.2.3. Takeda Pharmaceutical Company Limited
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. Financials (Based on Availability)
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. SWOT,Etc.
    • 10.2.4. Grifols, S.A.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. Financials (Based on Availability)
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. SWOT,Etc.
    • 10.2.5. Medix Biochemica
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. Financials (Based on Availability)
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. SWOT,Etc.
    • 10.2.6. Kedrion S.p.A.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. Financials (Based on Availability)
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. SWOT,Etc.
    • 10.2.7. Scripps Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. Financials (Based on Availability)
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 2: Global Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 3: Global Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 4: Global Human Antithrombin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 6: North America Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 7: North America Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 8: North America Human Antithrombin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 10: Europe Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 11: Europe Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Europe Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 14: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 15: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Human Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 18: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 19: Rest of the World Human Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034

List of Figures

  • Figure 1: Global Human Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Human Antithrombin Market Value Share (%), by Application, 2025 & 2034
  • Figure 3: Global Human Antithrombin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Human Antithrombin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Human Antithrombin Market Value (USD million), by Region, 2025 & 2034
  • Figure 6: North America Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 7: North America Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 8: North America Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 9: North America Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 10: North America Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 11: North America Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 12: North America Human Antithrombin Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Human Antithrombin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 15: Europe Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 16: Europe Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 17: Europe Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 18: Europe Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 20: Europe Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 21: Europe Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Europe Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Asia Pacific Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 24: Asia Pacific Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 25: Asia Pacific Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 26: Asia Pacific Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 27: Asia Pacific Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 28: Asia Pacific Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 29: Asia Pacific Human Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Asia Pacific Human Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Rest of the World Human Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Rest of the World Human Antithrombin Market Value Share (%), by Application, 2025
  • Figure 33: Rest of the World Human Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 34: Rest of the World Human Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 35: Rest of the World Human Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 36: Rest of the World Human Antithrombin Market Value Share (%), by End User, 2025
  • Figure 37: Global Human Antithrombin Market Share (%), By Company, 2025